SCHEMBL379543

SCHEMBL379543

Cc1ccc(-c2csc3c(-c4ccc(F)cc4)cnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
CDK8 P49336 2/20 0.44
CCNC P24863 1/20 0.44
PDE11A Q9HCR9 1/20 0.44
ESR1 P03372 1/20 0.43
PTGS2 P35354 1/20 0.43
TP53 P04637 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 2/20 0.42
HSD17B10 Q99714 2/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
AURKB Q96GD4 4/20 0.41
KDR P35968 3/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
AURKA O14965 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379874 0.94 CCNC (0.47) CDK8CCNCESR1TP53L3MBTL1
SCHEMBL379662 0.93 CCNC (0.49) CDK8CCNCESR1TP53L3MBTL1
SCHEMBL379947 0.91 KDR (0.45) CDK8CCNCPDE11AESR1TP53
SCHEMBL379876 0.90 BTK (0.47) CDK8CCNCESR1PTGS2TP53
SCHEMBL379860 0.90 CCNC (0.42) THRBCDK8CCNCESR1TP53
SCHEMBL379469 0.89 ESR1 (0.49) CDK8CCNCESR1TP53L3MBTL1
SCHEMBL379842 0.88 CYP1A2 (0.54) CDK8CCNCESR1TP53L3MBTL1
SCHEMBL379554 0.87 BRAF (0.52) CDK8CCNCESR1ALDH1A1MAPK1
SCHEMBL379872 0.85 CCNC (0.42) CDK8CCNCESR1TP53L3MBTL1
SCHEMBL380180 0.85 ESR1 (0.50) CDK8CCNCESR1TP53AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US claimed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 THRB 590/4885CDK8 1639/4885CCNC 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.